Total Payments
$3.6M
2024 Payments
$825,563
Companies
56
Transactions
4,621
Payment Breakdown by Category
Other$2.2M (61.4%)
Consulting$898,705 (25.0%)
Travel$396,264 (11.0%)
Food & Beverage$73,941 (2.1%)
Research$16,000 (0.4%)
Education$3,939 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.2M | 986 | 60.5% |
| Consulting Fee | $898,705 | 287 | 25.0% |
| Travel and Lodging | $396,264 | 1,218 | 11.0% |
| Food and Beverage | $73,941 | 2,034 | 2.1% |
| Honoraria | $28,256 | 11 | 0.8% |
| Unspecified | $16,000 | 6 | 0.4% |
| Education | $3,939 | 77 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,875 | 2 | 0.1% |
Payments by Type
General
$3.6M
4,615 transactions
Research
$16,000
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $593,522 | 878 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $589,633 | 526 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $371,680 | 494 | $0 (2024) |
| ABBVIE INC. | $365,300 | 366 | $0 (2024) |
| Axsome Therapeutics, Inc. | $244,995 | 191 | $0 (2024) |
| ITI, Inc. | $184,711 | 177 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $175,366 | 243 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $168,043 | 211 | $0 (2024) |
| Eisai Inc. | $122,262 | 173 | $0 (2021) |
| Allergan, Inc. | $116,461 | 267 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $825,563 | 722 | Axsome Therapeutics, Inc. ($152,276) |
| 2023 | $808,343 | 703 | Teva Pharmaceuticals USA, Inc. ($125,982) |
| 2022 | $659,699 | 616 | Teva Pharmaceuticals USA, Inc. ($187,866) |
| 2021 | $416,967 | 606 | Teva Pharmaceuticals USA, Inc. ($115,708) |
| 2020 | $282,347 | 549 | Eisai Inc. ($76,635) |
| 2019 | $300,638 | 709 | Neurocrine Biosciences, Inc. ($117,006) |
| 2018 | $265,865 | 553 | Neurocrine Biosciences, Inc. ($146,185) |
| 2017 | $39,178 | 163 | Neurocrine Biosciences, Inc. ($30,700) |
All Payment Transactions
4,621 individual payment records from CMS Open Payments — Page 1 of 185
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,765.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $634.57 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $497.99 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $274.31 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $122.10 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $23.98 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $19.75 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $579.46 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $544.27 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $306.34 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $105.88 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $20.93 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/13/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,808.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,765.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Consulting Fee | Cash or cash equivalent | $1,550.00 | General |
| Category: Neurology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $778.42 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $758.28 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $244.93 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $232.56 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $99.11 | General |
| Category: Neuropsychiatry | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $16,000 | 6 |
About Dr. Craig Chepke, M.D
Dr. Craig Chepke, M.D is a Psychiatry healthcare provider based in Huntersville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/22/2008. The National Provider Identifier (NPI) number assigned to this provider is 1831363712.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Craig Chepke, M.D has received a total of $3.6M in payments from pharmaceutical and medical device companies, with $825,563 received in 2024. These payments were reported across 4,621 transactions from 56 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.2M).
Ad
Practice Information
- Specialty Psychiatry
- Location Huntersville, NC
- Active Since 04/22/2008
- Last Updated 01/07/2022
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1831363712
Products in Payments
- INGREZZA (Drug) $588,029
- VRAYLAR (Drug) $477,007
- AUSTEDO (Drug) $357,918
- CAPLYTA (Drug) $271,486
- REXULTI (Drug) $230,160
- SPRAVATO (Drug) $182,372
- Auvelity (Drug) $163,226
- NUPLAZID (Drug) $163,043
- Dayvigo (Drug) $122,193
- ABILIFY MYCITE (Drug) $106,259
- Austedo XR (Drug) $89,401
- UZEDY (Drug) $82,842
- Sunosi (Drug) $81,769
- Trintellix (Drug) $66,043
- LYBALVI (Drug) $63,917
- ABILIFY MAINTENA (Drug) $56,799
- AZSTARYS (Drug) $38,882
- COBENFY (Drug) $27,020
- SUNOSI (Drug) $25,592
- SECUADO (Drug) $22,976
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.